Europe PMC
Do data resources managed by EMBL-EBI and our collaborators make a difference to your work?
If so, please take 10 minutes to fill in our survey, and help us make the case for why sustaining open data resources is critical for life sciences research.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Malignant or accelerated hypertension.

The Western Journal of Medicine, 01 Apr 1984, 140(4):575-582
PMID: 6372248 PMCID: PMC1021775

ReviewFree full text in Europe PMC

Abstract 

Malignant or accelarated hypertension is a life-threatening medical emergency that is a possible complication of practically any hypertensive disorder. If not promptly treated it can cause severe, rapidly progressive target-organ damage and death. While the histo-pathologic features of malignant hypertension are well recognized, the pathogenesis of the associated vascular lesions and the transition from a benign to a malignant phase are unclear. With adequate control of hypertension, progression to the accelarated or malignant phase can be prevented. Moreover, promptly and effectively reducing the blood pressure during the malignant phase can prevent, minimize or even reverse serious target organ injury. Malignant hypertension, therefore, is both preventable and treatable.

Free full text 

Logo of westjmedLink to Publisher's site
West J Med. 1984 Apr; 140(4): 575–582.
PMCID: PMC1021775
PMID: 6372248

Malignant or Accelarated Hypertension

N. D. Vaziri, MD
Copyright and License information Disclaimer

Abstract

Malignant or accelarated hypertension is a life-threatening medical emergency that is a possible complication of practically any hypertensive disorder. If not promptly treated it can cause severe, rapidly progressive target-organ damage and death. While the histo-pathologic features of malignant hypertension are well recognized, the pathogenesis of the associated vascular lesions and the transition from a benign to a malignant phase are unclear. With adequate control of hypertension, progression to the accelarated or malignant phase can be prevented. Moreover, promptly and effectively reducing the blood pressure during the malignant phase can prevent, minimize or even reverse serious target organ injury. Malignant hypertension, therefore, is both preventable and treatable.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.6M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
 
icon of scanned page 575
575
icon of scanned page 576
576
icon of scanned page 577
577
icon of scanned page 578
578
icon of scanned page 579
579
icon of scanned page 580
580
icon of scanned page 581
581
icon of scanned page 582
582
 

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Möhring J, Petri M, Szokol M, Haack D, Möhring B. Effects of saline drinking on malignant course of renal hypertension in rats. Am J Physiol. 1976 Mar;230(3):849–857. [Abstract] [Google Scholar]
  • HARINGTON M, KINCAID-SMITH P, McMICHAEL J. Results of treatment in malignant hypertension: a seven-year experience in 94 cases. Br Med J. 1959 Nov 14;2(5158):969–980. [Europe PMC free article] [Abstract] [Google Scholar]
  • Perry HM, Jr, Schroeder HA, Catanzaro FJ, Moore-Jones D, Camel GH. Studies on the control of hypertension. 8. Mortality, morbidity, and remissions during twelve years of intensive therapy. Circulation. 1966 Jun;33(6):958–972. [Abstract] [Google Scholar]
  • Woods JW, Blythe WB, Huffines WD. Management of malignant hypertension complicated by renal insufficiency. A follow-up study. N Engl J Med. 1974 Jul 4;291(1):10–14. [Abstract] [Google Scholar]
  • Zacherle BJ, Richardson JA. Irreversible renal failure secondary to hypertension induced by oral contraceptives. Ann Intern Med. 1972 Jul;77(1):83–85. [Abstract] [Google Scholar]
  • Dunn FG, Jones JV, Fife R. Malignant hypertension associated with use of oral contraceptives. Br Heart J. 1975 Mar;37(3):336–338. [Europe PMC free article] [Abstract] [Google Scholar]
  • SWORN BR. Total cystectomy. Br Med J. 1949 Feb 5;1(4596):221–223. [Europe PMC free article] [Abstract] [Google Scholar]
  • Razzak IA, Bauer W, Itzel W. Hepatitis-B-antigenemia with panarteritis, diffuse proliferative glomerulitis and malignant hypertension. Am J Gastroenterol. 1975 Jun;63(6):476–480. [Abstract] [Google Scholar]
  • Oldershaw PJ, Edmondson RP. Renal tuberculosis presenting with accelerated hypertension. Tubercle. 1978 Sep;59(3):197–199. [Abstract] [Google Scholar]
  • Medsger TA, Jr, Masi AT, Rodnan GP, Benedek TG, Robinson H. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med. 1971 Sep;75(3):369–376. [Abstract] [Google Scholar]
  • Medsger TA, Jr, Masi AT. Survival with scleroderma. II. A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients. J Chronic Dis. 1973 Oct;26(10):647–660. [Abstract] [Google Scholar]
  • Beevers DG, Brown JJ, Ferriss JB, Fraser R, Lever AF, Robertson JI, Tree M. Renal abnormalities and vascular complications in primary hyperaldosteronism. Evidence on tertiary hyperaldosteronism. Q J Med. 1976 Jul;45(179):401–410. [Abstract] [Google Scholar]
  • Aloia JF, Beutow G. Malignant hypertension with aldosteronoma producing adenoma. Am J Med Sci. 1974 Oct;268(4):241–245. [Abstract] [Google Scholar]
  • Baglin A, Weiss Y, Safar M, Milliez P. Hyperaldostéronisme primaire avec hypertension maligne. Nouv Presse Med. 1973 Feb 3;2(5):295–297. [Abstract] [Google Scholar]
  • George JM, Wright L, Bell NH, Bartter FC. The syndrome of primary aldosteronism. Am J Med. 1970 Mar;48(3):343–356. [Abstract] [Google Scholar]
  • Del Greco F, Dolkart R, Skom J, Method H. Association of accelerated (malignant) hypertension in a patient with primary aldosteronism. J Clin Endocrinol Metab. 1966 Aug;26(8):808–814. [Abstract] [Google Scholar]
  • KAPLAN NM. PRIMARY ALDOSTERONISM WITH MALIGNANT HYPERTENSION. N Engl J Med. 1963 Dec 12;269:1282–1286. [Abstract] [Google Scholar]
  • McAllister RG, Jr, Van Way CW, 3rd, Dayani K, Anderson WJ, Temple E, Michelakis AM, Coppage WS, Jr, Oates JA. Malignant hypertension: effect of therapy on renin and aldosterone. Circ Res. 1971 May;28(5 Suppl):160–174. [Abstract] [Google Scholar]
  • Harrison TS, Birbari A, Seaton JF. Malignant hypertension in pheochromocytoma: correlation with plasma renin activity. Johns Hopkins Med J. 1972 May;130(5):329–332. [Abstract] [Google Scholar]
  • PERERA GA. The accelerated form of hypertension: a unique entity. Trans Assoc Am Physicians. 1958;71:62–68. [Abstract] [Google Scholar]
  • HEPTINSTALL RH. Renal biopsies in hypertension. Br Heart J. 1954 Apr;16(2):133–141. [Europe PMC free article] [Abstract] [Google Scholar]
  • Allison PR, Bleehan N, Brown W, Pickering GW, Robb-Smith AH, Russell RP. The production and resolution of hypertensive vascular lesions in the rabbit. Clin Sci. 1967 Aug;33(1):39–51. [Abstract] [Google Scholar]
  • McCORMACK LJ, BELAND JE, SCHNECKLOTH RE, CORCORAN AC. Effects of antihypertensive treatment on the evolution of the renal lesions in malignant nephrosclerosis. Am J Pathol. 1958 Nov-Dec;34(6):1011–1021. [Europe PMC free article] [Abstract] [Google Scholar]
  • FLOYER MA. The effect of nephrectomy and adrenalectomy upon the blood pressure in hypertensive and normotensive rats. Clin Sci (Lond) 1951 Nov;10(4):405–421. [Abstract] [Google Scholar]
  • OLD JW, RUSSELL WO. Necrotizing pulmonary arteritis occurring with congenital heart disease (Eisenmenger complex); report of case with necropsy. Am J Pathol. 1950 Sep;26(5):789–805. [Europe PMC free article] [Abstract] [Google Scholar]
  • SYMMERS WSC. Necrotizing pulmonary arteriopathy associated with pulmonary hypertension. J Clin Pathol. 1952 Feb;5(1):36–41. [Europe PMC free article] [Abstract] [Google Scholar]
  • RODNAN GP, SCHREINER GE, BLACK RL. Renal involvement in progressive systemic sclerosis (generalized scleroderma). Am J Med. 1957 Sep;23(3):445–462. [Abstract] [Google Scholar]
  • KAHN JR, SKEGGS LT, Jr, SHUMWAY NP, WISENBAUGH PE. The assay of hypertensin from the arterial blood of normotensive and hypertensive human beings. J Exp Med. 1952 Jun;95(6):523–529. [Europe PMC free article] [Abstract] [Google Scholar]
  • Catt KJ, Cran E, Zimmet PZ, Best JB, Cain MD, Coghlan JP. Angiotensin II blood-levels in human hypertension. Lancet. 1971 Mar 6;1(7697):459–464. [Abstract] [Google Scholar]
  • MASSON GMC, PLAHL G, CORCORAN AC, PAGE IH. Accelerated hypertensive vascular disease from saline and renin in nephrectomized dogs. AMA Arch Pathol. 1953 Feb;55(2):85–97. [Abstract] [Google Scholar]
  • GIESE J. PATHOGENESIS OF VASCULAR DISEASES CAUSED BY ACUTE RENAL ISCHAEMIA. Acta Pathol Microbiol Scand. 1963;59:417–427. [Abstract] [Google Scholar]
  • ASSCHER AW, ANSON SG. A vascular permeability factor of renal origin. Nature. 1963 Jun 15;198:1097–1098. [Abstract] [Google Scholar]
  • Goldby FS, Beilin LJ. How an acute rise in arterial pressure damages arterioles. Electron microscopic changes during angiotensin infusion. Cardiovasc Res. 1972 Sep;6(5):569–584. [Abstract] [Google Scholar]
  • Robertson AL, Khairallah PA. Effects of angiotensin II and some analogues on vascular permeability in the rabbit. Circ Res. 1972 Dec;31(6):923–931. [Abstract] [Google Scholar]
  • GIESE J. ACUTE HYPERTENSIVE VASCULAR DISEASE. 1. RELATION BETWEEN BLOOD PRESSURE CHANGES AND VASCULAR LESIONS IN DIFFERENT FORMS OF ACUTE HYPERTENSION. Acta Pathol Microbiol Scand. 1964;62:481–496. [Abstract] [Google Scholar]
  • HERBERTSON BM, KELLAWAY TD. Arterial necrosis in the rat produced by methoxamine. J Pathol Bacteriol. 1960 Jul;80:87–92. [Abstract] [Google Scholar]
  • Gross F. Niere und Hochdruck. Klin Wochenschr. 1972 Jul 1;50(13):621–635. [Abstract] [Google Scholar]
  • Gross F. The renin-angiotensin system and hypertension. Ann Intern Med. 1971 Nov;75(5):777–787. [Abstract] [Google Scholar]
  • Brunner HR, Kirshman JD, Sealey JE, Laragh JH. Hypertension of renal origin: evidence for two different mechanisms. Science. 1971 Dec 24;174(4016):1344–1346. [Abstract] [Google Scholar]
  • Gavras H, Brown WC, Brown JJ, Lever AF, Linton AL, MacAdam RF, McNicol GP, Robertson JI, Wardrop C. Microangipathic hemolytic anemia and the development of the malignant phase of hypertension. Circ Res. 1971 May;28(5 Suppl):127–142. [Abstract] [Google Scholar]
  • BRAIN MC, DACIE JV, HOURIHANE DO. Microangiopathic haemolytic anaemia: the possible role of vascular lesions in pathogenesis. Br J Haematol. 1962 Oct;8:358–374. [Abstract] [Google Scholar]
  • Linton AL, Gavras H, Gleadle RI, Hutchison HE, Lawson DH, Lever AF, Macadam RF, McNicol GP, Robertson JI. Microangiopathic haemolytic anaemia and the pathogenesis of malignant hypertension. Lancet. 1969 Jun 28;1(7609):1277–1282. [Abstract] [Google Scholar]
  • Dauda G, Möhring J, Hofbauer KG, Homsy E, Miksche U, Orth H, Gross F. The vicious circle in acute malignant hypertension of rats. Clin Sci Mol Med Suppl. 1973 Aug;45 (Suppl 1):251s–2515. [Abstract] [Google Scholar]
  • Click RL, Joyner WL, Gilmore JP. Reactivity of gomerular afferent and efferent arterioles in renal hypertension. Kidney Int. 1979 Feb;15(2):109–115. [Abstract] [Google Scholar]
  • FISHER ER, RODNAN GP. Pathologic observations concerning the kidney in progressive systemic sclerosis. AMA Arch Pathol. 1958 Jan;65(1):29–39. [Abstract] [Google Scholar]
  • PARONETTO F. IMMUNOCYTOCHEMICAL OBSERVATIONS ON THE VASCULAR NECROSIS AND RENAL GLOMERULAR LESIONS OF MALIGNANT NEPHROSCLEROSIS. Am J Pathol. 1965 Jun;46:901–915. [Europe PMC free article] [Abstract] [Google Scholar]
  • Spargo BH, Ordóez NG, Ringus JC. The differential diagnosis of crescentic glomerulonephritis. The pathology of specific lesions with prognostic implications. Hum Pathol. 1977 Mar;8(2):187–204. [Abstract] [Google Scholar]
  • Hoyer JR, Michael AF, Hoyer LW. Immunofluorescent localization of antihemophilic factor antigen and fibrinogen in human renal diseases. J Clin Invest. 1974 May;53(5):1375–1384. [Europe PMC free article] [Abstract] [Google Scholar]
  • Burkholder PM. Malignant nephrosclerosis. Arch Pathol. 1965 Dec;80(6):583–589. [Abstract] [Google Scholar]
  • Simon NM, Graham MB, Kyser FA, Gashti EN. Resolution of renal failure with malignant hypertension in scleroderma. Case report and review of the literature. Am J Med. 1979 Sep;67(3):533–539. [Abstract] [Google Scholar]
  • Cordingley FT, Jones NF, Wing AJ, Hilton PJ. Reversible renal failure in malignant hypertension. Clin Nephrol. 1980 Aug;14(2):98–103. [Abstract] [Google Scholar]
  • Pickering G. Reversibility of malignant hypertension. Follow-up of three cases. Lancet. 1971 Feb 27;1(7696):413–418. [Abstract] [Google Scholar]
  • SCHOTTSTAEDT MF, SOKOLOW M. The natural history and course of hypertension with papilledema (malignant hypertension). Am Heart J. 1953 Mar;45(3):331–362. [Abstract] [Google Scholar]
  • Kincaid-Smith P, Hua AS, Myers JB, MacDonald I, Fang P. Prazosin and hydrallazine in the treatment of hypertension. Clin Sci Mol Med Suppl. 1976 Dec;3:617s–619s. [Abstract] [Google Scholar]
  • Padfield PL, Morton JJ. Proceedings: Application of a sensitive radioimmunoassay for plasma arginine vasopressin to pathological conditions in man. Clin Sci Mol Med. 1974 Sep;47(3):16P–17P. [Abstract] [Google Scholar]
  • Menard J, Meyer P, Milliez P. L'hypertension artérielle d'origine rénale: sécrétion inappropriée de rénine. Presse Med. 1967 Oct 14;75(42):2083–2085. [Abstract] [Google Scholar]
  • Finnerty FA., Jr Hypertensive crisis. JAMA. 1974 Sep 9;229(11):1479–1480. [Abstract] [Google Scholar]
  • Ledingham JG, Rajagopalan B. Cerebral complications in the treatment of accelerated hypertension. Q J Med. 1979 Jan;48(189):25–41. [Abstract] [Google Scholar]
  • Strandgaard S, Olesen J, Skinhoj E, Lassen NA. Autoregulation of brain circulation in severe arterial hypertension. Br Med J. 1973 Mar 3;1(5852):507–510. [Europe PMC free article] [Abstract] [Google Scholar]
  • Kaneda H, Yamauchi T, Murata T, Matsumoto J, Haruyama T. Treatment of malignant hypertension with infusion of sodium chloride; a case report and a review. Tohoku J Exp Med. 1980 Oct;132(2):179–186. [Abstract] [Google Scholar]
  • Thomas RD, Lee MR. Sodium repletion and beta-adrenergic blockade in treatment of salt depletion with accelerated hypertension. Br Med J. 1976 Dec 11;2(6049):1425–1426. [Europe PMC free article] [Abstract] [Google Scholar]
  • Kumar GK, Dastoor FC, Robayo JR, Razzaque MA. Side effects of diazoxide. JAMA. 1976 Jan 19;235(3):275–276. [Abstract] [Google Scholar]
  • Mizroch S, Yurasek M. Hypotension and bradycardia following diazoxide and hydralazine therapy. JAMA. 1977 Jun 6;237(23):2471–2472. [Abstract] [Google Scholar]
  • Kanada SA, Kanada DJ, Hutchinson RA, Wu D. Angina-like syndrome with diazoxide therapy for hypertensive crisis. Ann Intern Med. 1976 Jun;84(6):696–699. [Abstract] [Google Scholar]
  • Thien TA, Huysmans FT, Gerlag PG, Koene RA, Wijdeveld PG. Diazoxide infusion in severe hypertension and hypertensive crisis. Clin Pharmacol Ther. 1979 Jun;25(6):795–799. [Abstract] [Google Scholar]
  • Ram CV, Kaplan NM. Individual titration of diazoxide dosage in the treatment of severe hypertension. Am J Cardiol. 1979 Mar;43(3):627–630. [Abstract] [Google Scholar]
  • Spitalewitz S, Porush JG, Oguagha C. Use of oral clonidine for rapid titration of blood pressure in severe hypertension. Chest. 1983 Feb;83(2 Suppl):404–407. [Abstract] [Google Scholar]
  • Cohen IM, Katz MA. Oral clonidine loading for rapid control of hypertension. Clin Pharmacol Ther. 1978 Jul;24(1):11–15. [Abstract] [Google Scholar]
  • Anderson RJ, Hart GR, Crumpler CP, Reed WG, Matthews CA. Oral clonidine loading in hypertensive urgencies. JAMA. 1981 Aug 21;246(8):848–850. [Abstract] [Google Scholar]
  • Brain MC, Baker LR, McBride JA, Rubenberg ML, Dacie JV. Treatment of patients with microangiopathic haemolytic anaemia with heparin. Br J Haematol. 1968 Dec;15(6):603–621. [Abstract] [Google Scholar]
  • Kincaid-Smith P, Laver MC, Fairley KF. Dipyridamole and anticoagulants in renal disease due to glomerular and vascular lesions. A new approach to therapy. Med J Aust. 1970 Jan 24;1(4):145–151. [Abstract] [Google Scholar]
  • Mroczek WJ. Malignant hypertension: kidneys too good to be extirpated. Ann Intern Med. 1974 Jun;80(6):754–757. [Abstract] [Google Scholar]
  • Lee DB, Ehrlich RM, Dabir-Vaziri N, Sambhi MP, Doud RB, Barajas L, Schultze RG. Post-transplant hypertension. Normoreninemic severe hypertension treated by bilateral nephrectomies. Urology. 1977 Apr;9(4):425–428. [Abstract] [Google Scholar]
Articles from The Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

Citations & impact 

Impact metrics

6
Citations
Jump to Citations

Citations of article over time

Article citations

Go to all (6) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.